

MARKET REPORT



Multiple Myeloma - Japan Drug Forecast and Market Analysis to 2023

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Multiple Myeloma - Japan Drug Forecast and Market Analysis to 2023

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Multiple Myeloma - Japan Drug Forecast and Market Analysis to 2023

Multiple Myeloma - Japan Drug Forecast and Market Analysis to 2023

Summary

The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023. The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti and daratumumab, which will not only provide a new treatment option for MM patients, but will also lengthen the time between relapses, meaning that the duration of Revlimid and/or Velcade treatments will also be longer. Furthermore, the relatively mild safety profile of these mAbs and the significant efficacies demonstrated by these agents will mean that more MM patients will ultimately receive drug treatment. Label extensions of these mAbs, as well as of second-generation proteasome inhibitors ixazomib and Kyprolis, will further increase treatment options for these patients. The biggest constrainers of the MM market are the increasing cost-consciousness of healthcare providers, as the launch and subsequent label extensions of these pipeline agents will lead to a significant expense, which may impact uptake of these drugs. The patent expiries of Revlimid and Velcade will somewhat alleviate healthcare spending on multiple myeloma patients, which may assist in the uptake of mAbs and second-generation PIs in the multiple myeloma market.

Japan will experience significant market growth, driven by the uptake of the latest premium-priced therapies. KOLs identified the reimbursement of drugs in Japan as a significant barrier to market growth, although oncology drugs are generally reimbursed if they demonstrate clinically significant efficacy.

Scope

- Overview of Multiple Myeloma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting Japan Multiple Myeloma market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Multiple Myeloma.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2014-2024 in Japan.

Additional Details

Publisher : Global Data
Reference : GDHC305CFR
Number of Pages : 162
Report Format : PDF
Publisher Information :



GlobalData »

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Multiple Myeloma - Japan Drug Forecast and Market Analysis to 2023 [Published by Global Data]

- 1 Table of Contents1 Table of Contents 21.1 List of Tables 61.2 List of Figures 102 Introduction 112.1 Catalyst 112.2 Related Reports 122.3 Upcoming Related Reports 123 Disease Overview 133.1 Etiology and Pathophysiology 133.1.1 Etiology 133.1.2 Pathophysiology 133.2 Staging Systems 163.3 Response and Relapse Criteria 173.4 Symptoms 193.5 Prognosis 203.6 Quality of Life 214 Disease Management 244.1 Treatment Overview 244.2 Diagnosis 254.3 Clinical Practice 264.3.1 Primary Therapy for SCT-Eligible Patients 274.3.2 Primary Therapy for Non-SCT Patients 294.3.3 Salvage/Relapse Therapy 304.3.4 Leading Prescribed Drugs 314.4 Japan 344.4.1 Diagnosis 354.4.2 Clinical Practice 355 Competitive Assessment 375.1 Overview 375.2 Product Profiles - Proteasome Inhibitors 375.2.1 Velcade (Bortezomib) 375.2.2 Kyprolis (Carfilzomib) 445.3 Product Profiles - Immunomodulators 525.3.1 Revlimid (Lenalidomide) 525.3.2 Pomalyst/Imnovid (Pomalidomide) 595.4 Other Therapeutic Classes 646 Unmet Need and Opportunity 656.1 Overview 656.2 Treatment of High-Risk Patients 656.2.1 Unmet Need 656.2.2 Gap Analysis 666.2.3 Opportunity 676.3 Treatment of Patients with Smoldering Myeloma 676.3.1 Unmet Need 676.3.2 Gap Analysis 696.3.3 Opportunity 696.4 Treatment of Extramedullary Disease 706.4.1 Unmet Need 706.4.2 Gap Analysis 706.4.3 Opportunity 717 Pipeline Assessment 727.1 Overview 727.2 Promising Drugs in Clinical Development 727.2.1 Farydak (Panobinostat) 727.2.2 Ixazomib 797.2.3 Emlipicit (Elotuzumab) 847.2.4 Daratumumab 907.2.5 Aplidin (Plitidepsin) 957.3 Promising Drugs in Early-Stage Development 997.3.1 Oprozomib (ONX-0912) 997.3.2 Filanesib 1007.3.3 SAR650984 1007.3.4 Marizomib 1027.3.5 Evofosfamide 1027.3.6 LGH447 1037.3.7 Selinexor (KPT-330) 1038 Market Outlook 1058.1 Japan 1058.1.1 Forecast 1058.1.2 Key Events 1088.1.3 Drivers - Japan 1088.1.4 Barriers - Japan 1099 Appendix 1119.1 Bibliography 1119.2 Abbreviations 1339.3 Methodology 1379.4 Forecasting Methodology 1379.4.1 Diagnosed Multiple Myeloma Patients 1379.4.2 Percent of Drug-Treated Patients 1389.4.3 Drugs Included in Each Therapeutic Class 1389.4.4 Launch and Patent Expiry Dates 1399.4.5 General Pricing Assumptions 1409.4.6 Individual Drug Assumptions 1419.4.7 Pricing of Pipeline Agents 1489.4.8 Generic Erosion 1559.5 Primary Research - KOLs Interviewed for this Report 1569.6 Primary Research - High-Prescriber Survey 1589.7 About the Authors 1599.7.1 Analyst 1599.7.2 Therapy Director 1599.7.3 Epidemiologist 1609.7.4 Global Head of Healthcare 1609.8 About GlobalData 1619.9 Disclaimer 161

List Of Tables in Multiple Myeloma - Japan Drug Forecast and Market Analysis to 2023 [Published by Global Data]

1.1 List of Tables

Table 1: Definition of the Classes of Myeloma 15

Table 2: Staging Systems for Multiple Myeloma 17

Table 3: IMWG Uniform Response Criteria for Multiple Myeloma: Response 18

Table 4: IMWG Uniform Response Criteria for Multiple Myeloma: Progression 18

Table 5: Symptoms of Multiple Myeloma 19

Table 6: Median Survival for Each Stage at Diagnosis of Multiple Myeloma 20

Table 7: Potential Diagnostic Markers that Predict Two-Year Disease Progression 21

Table 8: Summary of Prevalence and Clinical Outcomes of Translocations in Multiple Myeloma 21

Table 9: Treatment Guidelines for Multiple Myeloma 25

Table 10: Definition of the Classes of Myeloma 26

Table 11: Most Prescribed Drugs for Multiple Myeloma by Class in the Global Markets, 2014 31

Table 12: Most-Prescribed Drugs for Multiple Myeloma by Segment in the Global Markets, 2013 32

Table 13: Country Profile - Japan 34

Table 14: Product Profile - Velcade 38

Table 15: Results from the Pivotal Phase III APEX Trial for Velcade 40

Table 16: Results from the Pivotal Phase III VISTA Trial for Velcade 41

Table 17 Results from the Subcutaneous versus Intravenous Velcade Phase III trial 41

Table 18: Common Grade 3 and 4 Adverse Events from Velcade Pivotal Clinical Trials 42

Table 19: Velcade SWOT Analysis, 2015 43

Table 20: Global Sales Forecast (\$m) for Velcade, 2013-2023 43

Table 21: Product Profile - Kyprolis 45

Table 22 Summary of Phase III Pivotal Trial Results for Kyprolis 48

Table 23: Summary of Phase II Clinical Trial Efficacy Data for Kyprolis 49

Table 24 Summary of Adverse Events from Key Phase III Pivotal Trials for Kyprolis 50

Table 25: Kyprolis SWOT Analysis, 2015 51

Table 26: Global Sales Forecasts (\$m) for Kyprolis, 2013-2023 52

Table 27: Product Profile - Revlimid 53

Table 28 Summary of Phase III Pivotal Trial Results for Revlimid in NDMM Patients	55
Table 29 Summary of Phase III Pivotal Trial Results for Revlimid in RRMM Patients	56
Table 30: Summary of Frequent Grade 3 and 4 AEs in a Phase III Trial for Revlimid	57
Table 31: Revlimid SWOT Analysis, 2015	58
Table 32: Global Sales Forecast (\$m) for Revlimid, 2013-2023	58
Table 33: Product Profile - Pomalyst	59
Table 34: Summary of PFS, OS, and ORR from Phase II Trial Data for Pomalyst	61
Table 35: Summary of Phase III Trial Data for Pomalyst	62
Table 36: Pomalyst SWOT Analysis, 2015	63
Table 37: Global Sales Forecasts (\$m) for Pomalyst, 2013-2023	63
Table 38: Summary of Other Therapeutic Classes, 2015	64
Table 39: Pipeline Product Profile - Farydak	73
Table 40: Summary of the Phase III PANORAMA 1 Trial of Farydak	76
Table 41: Summary of the Phase III PANORAMA 1 Trial of Farydak in Patients Who Received at Least Two Prior Lines of Therapy (Including Velcade and an IMiD)	76
Table 42: Summary of the Phase II PANORAMA 2 Trial of Farydak	77
Table 43: Grade 3-4 Adverse Events in the Phase III PANORAMA 1 Trial of Farydak	77
Table 44: Farydak SWOT Analysis, 2015	79
Table 45: Global Sales Forecast (\$m) for Farydak, 2013-2023	79
Table 46: Pipeline Product Profile - Ixazomib	80
Table 47: Response Results from the Phase II Study of Ixazomib	82
Table 48: Ixazomib SWOT Analysis, 2015	83
Table 49: Global Sales Forecast (\$m) for Ixazomib, 2013-2023	84
Table 50: Pipeline Product Profile - Empliciti	85
Table 51: Summary of the Phase III ELOQUENT 2 trial of Empliciti	87
Table 52: Efficacy Results from the Phase II Study of Empliciti with Velcade and Dexamethasone	88
Table 53: Empliciti SWOT Analysis, 2015	89
Table 54: Global Sales Forecast (\$m) for Empliciti, 2013-2023	89
Table 55: Pipeline Product Profile - Daratumumab	90
Table 56: Response Results from the Phase II Study of Daratumumab	92
Table 57: Daratumumab SWOT Analysis, 2015	94

Table 58: Global Sales Forecast (\$m) for Ddaratumumab, 2013-2023	94
Table 59: Pipeline Product Profile - Aplidin	95
Table 60: Summary of Phase II Clinical Trial Results for Aplidin	97
Table 61: Summary of Grade 3 and 4 Adverse Events of Aplidin	97
Table 62: Aplidin SWOT Analysis, 2015	98
Table 63: Global Sales Forecast (\$m) for Aplidin, 2013-2023	98
Table 64: Summary of Efficacy Data from the Phase Ib/II Clinical Trial of Oprozomib	100
Table 65: Summary of the Phase I Efficacy Results of SAR650984	101
Table 66: Summary of the Phase I Efficacy Results of Evofosfamide	103
Table 67: Japan Sales Forecasts, Multiple Myeloma, 2013-2023 (\$m)	105
Table 68: Key Events Impacting Sales for Multiple Myeloma in Japan, 2013-2023	108
Table 69: Japanese Multiple Myeloma - Drivers, 2013-2023	108
Table 70: Japanese Multiple Myeloma - Barriers, 2013-2023	109
Table 71: Multiple Myeloma Diagnosed Incidence, 2013-2023	138
Table 72: Multiple Myeloma Drugs and Pipeline agents, Launch Dates	139
Table 73: Multiple Myeloma Drugs and Pipeline agents, Anticipated Patent Expiries	140
Table 74: Average Cost of Therapy for Velcade	142
Table 75: Average Duration of Treatment (Weeks) for Velcade	142
Table 76: Average Cost of Therapy for Kyprolis (\$)	144
Table 77: Average Duration of Treatment (Weeks) for Kyprolis	144
Table 78: Average Cost of Therapy for Revlimid (\$)	145
Table 79: Average Duration of Treatment (Weeks) for Revlimid	146
Table 80: Average Cost of Therapy for Pomalyst/Imnovid (\$)	147
Table 81 Average Duration of Treatment (Weeks) for Pomalyst/Imnovid	147
Table 82: Average Cost of Therapy for Farydak (\$)	148
Table 83: Duration of Treatment (Weeks) for Farydak	149
Table 84: Average Cost of Therapy for Ixazomib (\$)	150
Table 85: Duration of Treatment (Weeks) for Ixazomib	150
Table 86: Average Cost of Therapy for Empliciti (\$)	151
Table 87: Duration of Treatment (Weeks) for Empliciti	152
Table 88: Average Cost of Therapy for Daratumumab (\$)	153

Table 89: Duration of Treatment (Weeks) for Daratumumab 154

Table 90: Average Cost of Therapy for Daratumumab (\$) 155

Table 91: Duration of Treatment (Weeks) for Daratumumab 155

Table 92: Numbers of Prescribers Surveyed in Each Country 158

List Of Figures, Charts and Diagrams in Multiple Myeloma - Japan Drug Forecast and Market Analysis to 2023 [Published by Global Data]

1.2 List of Figures

Figure 1: SCT-Eligible Typical Patient Journey 27

Figure 2: Non-SCT-Eligible Typical Patient Journey 29

Figure 3: Velcade's Phase III Development in Multiple Myeloma 39

Figure 4: Kyprolis's Phase III Development in Multiple Myeloma 46

Figure 5: Revlimid's Phase III Development in Multiple Myeloma 53

Figure 6: Pomalyst/Imnovid's Phase III Development in Multiple Myeloma 60

Figure 7: Farydak's Development in Multiple Myeloma 75

Figure 8: Dosing Schedule for Farydak 78

Figure 9: Ixazomib's Development in Multiple Myeloma 81

Figure 10: Empliciti's Development in Multiple Myeloma 85

Figure 11: Daratumumab's Development in Multiple Myeloma 92

Figure 12: Annual Japanese Sales for Multiple Myeloma by Drug, 2013-2023 106

Figure 13: Japanese Sales for Multiple Myeloma by Drug, 2013 and 2023 107

How to Buy...

Multiple Myeloma - Japan Drug Forecast and Market Analysis to 2023 [Published by Global Data]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/27217>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$4995** | Single User Price
- \$9990** | Site License Price
- \$14985** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.